Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07078591RecruitingPhase 2
Venetoclax with mini transplant for new AML
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
BeijingAges 18 years+ - NCT07066397RecruitingPhase 1
CAR-T cell therapy for relapsed B-cell ALL
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
TaipeiAges 18 years+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
Palo Alto, CaliforniaAges 1 year+ - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT06718244RecruitingPhase 2
CNCT19 for B-ALL with minimal remaining cancer after first remission
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT07059975RecruitingEarly Phase 1
Improved monitoring and treatment for pediatric acute myeloid leukemia
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
Houston, TexasAges 1 month–30 years - NCT07059156RecruitingPhase 2/Phase 3
Chemotherapy and transplant for adult ALL
This trial is testing a combination of chemotherapy and stem cell transplant for adults with Acute Lymphoblastic Leukemia (ALL). It aims to find the best way to treat ALL and improve survival. If you are diagnosed with ALL and are between 18 and 60 years old, you may be a candidate.
Taiyuan, ShanxiAges 18–60 - NCT07052916Recruiting
Music therapy for thinking and memory after blood cancer
This study tests whether music therapy can help blood cancer survivors who have trouble with thinking, memory, or concentration. It is for people with lymphoma, leukemia, or myeloma whose disease is stable or in remission.
Basking Ridge, New JerseyAges 18 years+ - NCT07051525Recruiting
Early vs. late stopping of antibiotics for fever in blood cancer treatment
This trial compares stopping antibiotics early (after fever resolves) versus continuing them as usual in adults with blood cancers who develop fever during treatment. It aims to find the best timing to reduce unnecessary antibiotic use.
Melbourne, VictoriaAges 18 years+ - NCT07048535Recruiting
Long-term follow-up study for CAR T-cell therapy patients
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
Memphis, TennesseeAges Any age - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07039877RecruitingPhase 2
Low-dose venetoclax with itraconazole and TACL for relapsed or refractory ALL
This trial tests a combination of low-dose venetoclax (a targeted cancer pill) plus itraconazole (an antifungal) and chemotherapy drugs for adults with acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to first treatment.
Monterrey, Nuevo LeónAges 16–45 - NCT06696183RecruitingPhase 2
Gilteritinib with venetoclax and azacitidine for FLT3-positive AML
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
DresdenAges 18 years+ - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Boston, MassachusettsAges 18–130 - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT07025824RecruitingPhase 2
Comparing two chemo drugs for stem cell transplant in AML and MDS
This trial compares two chemotherapy drugs, treosulfan and melphalan, used before a stem cell transplant in people with AML or MDS. The goal is to see which one works better with a special anti-rejection drug called PTCy.
AachenAges 18 years+ - NCT07028086RecruitingPhase 2
VAM for secondary or extramedullary AML
This trial tests a combination of three drugs (called VAM) in people whose acute myeloid leukemia (AML) is either secondary (came from another blood disorder), therapy-related (caused by previous cancer treatment), or has spread outside the bone marrow (extramedullary disease). It is for patients who have not yet received any treatment for their AML.
ShanghaiAges 18–65 - NCT07030400Recruiting
Quality of life study for adults with CLL or SLL
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Tampa, FloridaAges 18 years+ - NCT07019155Recruiting
DDX41 gene study for families with cancer risk
This study looks at people and families who have changes in the DDX41 gene or similar genes that may increase the risk of cancer. By joining, you can help researchers learn more about these gene changes and how they affect health.
Bethesda, MarylandAges 1 month–120 years
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.